A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Inclusion Criteria

• •1. The patient signs the informed consent form and voluntarily participate in this study;
• •2. Age ≥18 years;
• •3. Have the ability to read and understand Chinese;
• •4. Pathologically or histologically confirmed diagnosis of non-myeloid malignant tumor diseases (including solid tumors and malignant hematologic tumors);
• •5. Patients who plan to receive at least two consecutive cycles of anti-tumor trerapy based on a moderate to high FN risk chemotherapy regimen (see Appendix 4 for details of the chemotherapy regimen);
• •6. The investigator determines that the patient are eligible to receive administration of HHPG-19K injection and Auto-HHPG-19K injection (delivered through an adhesive patch automatic drug delivery device);
• •7. ECOG (Eastern Cooperative Oncology Group score) score 0-1 points;
• •8. Expected survival ≥3 months;
• •9. Good function of major organs, meeting the following criteria:
• •1. Neutrophil count ≥1.5 ×109/L;
• •2. Platelet count≥75 ×109/L;
• •3. Hemoglobin level≥80 g/L.
• •10. Women of childbearing age must take a blood pregnancy test within 3 days before randomization, and the result is negative, and they should not be lactating. Female subjects of childbearing age and male subjects whose partners are women of childbearing age must agree to approach highly effective contraceptive methods from the day of signing the informed consent form until at least 6 months after the last administration (for female subjects) or 3 months after the last administration (for male subjects).